PVLA
PALVELLA THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$122.96
+2.21%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$121.93
From 52W high−22.24%
Volume270434.00
Market cap$1.77B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$121.93
From 52W high
−22.24%
Volume
270434.00
Market cap
$1.77B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−30.4x
P/E (TTM)
—
RSI (14)
37.5
MomentumView details →
1D Return
+2.21%
YTD Return
+17.99%
SummaryUpdated Jun 1, 2026
Palvella Therapeutics, Inc. (NASDAQ:PVLA) is a clinical-stage biopharmaceutical company founded in 2015 and based in Wayne, Pennsylvania. The company specializes in developing novel therapies for patients with serious and rare genetic skin diseases. Since its inception, Palvella has focused on advancing its lead product candidate through clinical trials, with a particular emphasis on treating conditions driven by the mTOR (mechanistic target of rapamycin) pathway. The company went public in 2015 and continues to operate as a development-stage biotechnology firm without commercial revenue.
Similar companies
Latest newsMore news →
PALVELLA THERAPEUTICS, INC. announced that it will present Phase 3 SELVA and Phase 2 TOIVA results, along with new pediatric analyses, at the 2026 PeDRA Annual Conference.5d agoPalvella Therapeutics director George M. Jenkins sold 27,500 shares of the company's common stock for about $4.17 million between September 11 and September 15, 2026, under a pre-arranged Rule 10b5-1 trading plan.34d ago